The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers

Cytokine and Growth Factor Reviews

Volumn 25, Issue 3, 2014, Pages 307-316

  Freitas, Christelle ^a,b   Desnoyer, Aude ^a,b   Meuris, Floriane ^a,b   Bachelerie, Françoise ^a,b   Balabanian, Karl ^a,b   Machelon, Véronique ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSERM   (France)

Author keywords

ACKR3 CXCR7; Cancer; CXCL12 SDF 1; CXCR4; Virus

Indexed keywords

BETA ARRESTIN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; STROMAL CELL DERIVED FACTOR 1; CHEMOKINE RECEPTOR CXCR; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; CXCR7 PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; RETINA S ANTIGEN; TUMOR PROTEIN;

BINDING AFFINITY; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; COLORECTAL CARCINOMA; EPSTEIN BARR VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS 1; LIGAND BINDING; METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SHORT SURVEY; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VIRUS; ANIMAL; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; VIROLOGY; VIRUS INFECTION;

ANIMALS; ARRESTIN; CHEMOKINE CXCL12; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; RECEPTORS, CXCR; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TUMOR VIRUS INFECTIONS;

EID: 84902079261     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.04.006     Document Type: Short Survey

References (100)

1. Duda D.G., Kozin S.V., Kirkpatrick N.D., Xu L., Fukumura D., Jain R.K. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?. Clin Cancer Res 2011, 17:2074-2080.
2. Rankin S.M. Chemokines and adult bone marrow stem cells. Immunol Lett 2012, 145:47-54.
3. Kryczek I., Lange A., Mottram P., Alvarez X., Cheng P., Hogan M., et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005, 65:465-472.
4. Teicher B.A., Fricker S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010, 16:2927-2931.
5. Balabanian K., Lagane B., Infantino S., Chow K.Y., Harriague J., Moepps B., et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005, 280:35760-35766.
6. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z., et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006, 203:2201-2213.
7. Bachelerie F., Ben-Baruch A., Burkhardt A.M., Combadiere C., Farber J.M., Graham G.J., et al. International Union of Pharmacology, LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 2014, 66:1-79.
8. Sierro F., Biben C., Martinez-Munoz L., Mellado M., Ransohoff R.M., Li M., et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A 2007, 104:14759-14764.
9. Libert F., Parmentier M., Lefort A., Dumont J.E., Vassart G. Complete nucleotide sequence of a putative G protein coupled receptor: RDC1. Nucl Acids Res 1990, 18:1917.
10. Heesen M., Berman M.A., Charest A., Housman D., Gerard C., Dorf M.E. Cloning and chromosomal mapping of an orphan chemokine receptor: mouse RDC1. Immunogenetics 1998, 47:364-370.
11. Joost P., Methner A. Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands. Genome Biol 2002, 3. [RESEARCH0063].
12. Graham G.J., Locati M., Mantovani A., Rot A., Thelen M. The biochemistry and biology of the atypical chemokine receptors. Immunol Lett 2012, 145:30-38.
13. Luker K.E., Steele J.M., Mihalko L.A., Ray P., Luker G.D. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene 2010, 29:4599-4610.
14. Balabanian K., Levoye A., Klemm L., Lagane B., Hermine O., Harriague J., et al. Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling. J Clin Invest 2008, 118:1074-1084.
15. Signoret N., Oldridge J., Pelchen-Matthews A., Klasse P.J., Tran T., Brass L.F., et al. Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol 1997, 139:651-664.
16. Canals M., Scholten D.J., de Munnik S., Han M.K., Smit M.J., Leurs R. Ubiquitination of CXCR7 controls receptor trafficking. PLoS ONE 2012, 7:e34192.
17. Marchese A., Benovic J.L. Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. J Biol Chem 2001, 276:45509-45512.
18. Marchese A., Trejo J. Ubiquitin-dependent regulation of G protein-coupled receptor trafficking and signaling. Cell Signal 2013, 25:707-716.
19. Hoffmann F., Muller W., Schutz D., Penfold M.E., Wong Y.H., Schulz S., et al. Rapid uptake and degradation of CXCL12 depend on CXCR7 carboxyl-terminal serine/threonine residues. J Biol Chem 2012, 287:28362-28377.
20. Ray P., Mihalko L.A., Coggins N.L., Moudgil P., Ehrlich A., Luker K.E., et al. Carboxy-terminus of CXCR7 regulates receptor localization and function. Int J Biochem Cell Biol 2012, 44:669-678.
21. Rajagopal S., Kim J., Ahn S., Craig S., Lam C.M., Gerard N.P., et al. Beta-arrestin- but not G protein-mediated signaling by the decoy receptor CXCR7. Proc Natl Acad Sci U S A 2010, 107:628-632.
22. Kumar R., Tripathi V., Ahmad M., Nath N., Mir R.A., Chauhan S.S., et al. CXCR7 mediated Gialpha independent activation of ERK and Akt promotes cell survival and chemotaxis in T cells. Cell Immunol 2012, 272:230-241.
23. Boldajipour B., Mahabaleshwar H., Kardash E., Reichman-Fried M., Blaser H., Minina S., et al. Control of chemokine-guided cell migration by ligand sequestration. Cell 2008, 132:463-473.
24. Ray P., Lewin S.A., Mihalko L.A., Lesher-Perez S.C., Takayama S., Luker K.E., et al. Secreted CXCL12 (SDF-1) forms dimers under physiological conditions. Biochem J 2012, 442:433-442.
25. Naumann U., Cameroni E., Pruenster M., Mahabaleshwar H., Raz E., Zerwes H.G., et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS ONE 2010, 5:e9175.
26. Berahovich R.D., Zabel B.A., Lewen S., Walters M.J., Ebsworth K., Wang Y., et al. Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels. Immunology 2014, 141:111-122.
27. Haege S., Einer C., Thiele S., Mueller W., Nietzsche S., Lupp A., et al. CXC chemokine receptor 7 (CXCR7) regulates CXCR4 protein expression and capillary tuft development in mouse kidney. PLoS ONE 2012, 7:e42814.
28. Sanchez-Alcaniz J.A., Haege S., Mueller W., Pla R., Mackay F., Schulz S., et al. Cxcr7 controls neuronal migration by regulating chemokine responsiveness. Neuron 2011, 69:77-90.
29. Uto-Konomi A., McKibben B., Wirtz J., Sato Y., Takano A., Nanki T., et al. CXCR7 agonists inhibit the function of CXCL12 by down-regulation of CXCR4. Biochem Biophys Res Commun 2013, 431:772-776.
30. Veldkamp C.T., Peterson F.C., Pelzek A.J., Volkman B.F. The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci 2005, 14:1071-1081.
31. Veldkamp C.T., Seibert C., Peterson F.C., De la Cruz N.B., Haugner J.C., Basnet H., et al. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal 2008, 1:ra4.
32. Thelen M., Thelen S. CXCR7 CXCR4 and CXCL12: an eccentric trio?. J Neuroimmunol 2008, 198:9-13.
33. Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330:1066-1071.
34. Percherancier Y., Berchiche Y.A., Slight I., Volkmer-Engert R., Tamamura H., Fujii N., et al. Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo-and heterodimers. J Biol Chem 2005, 280:9895-9903.
35. Decaillot F.M., Kazmi M.A., Lin Y., Ray-Saha S., Sakmar T.P., Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem 2011, 286:32188-32197.
36. Kramp B.K., Sarabi A., Koenen R.R., Weber C. Heterophilic chemokine receptor interactions in chemokine signaling and biology. Exp Cell Res 2011, 317:655-663.
37. Levoye A., Balabanian K., Baleux F., Bachelerie F., Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009, 113:6085-6093.
38. Hartmann T.N., Grabovsky V., Pasvolsky R., Shulman Z., Buss E.C., Spiegel A., et al. A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J Leuk Biol 2008, 84:1130-1140.
39. Hattermann K., Held-Feindt J., Lucius R., Muerkoster S.S., Penfold M.E., Schall T.J., et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 2010, 70:3299-3308.
40. Miao Z., Luker K.E., Summers B.C., Berahovich R., Bhojani M.S., Rehemtulla A., et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 2007, 104:15735-15740.
41. Maishi N., Ohga N., Hida Y., Akiyama K., Kitayama K., Osawa T., et al. CXCR7: a novel tumor endothelial marker in renal cell carcinoma. Pathol Int 2012, 62:309-317.
42. Schutyser E., Su Y., Yu Y., Gouwy M., Zaja-Milatovic S., Van Damme J., et al. Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur Cytokine Netw 2007, 18:59-70.
43. Esencay M., Sarfraz Y., Zagzag D. CXCR7 is induced by hypoxia and mediates glioma cell migration towards SDF-1alpha. BMC Cancer 2013, 13:347.
44. Liu H., Xue W., Ge G., Luo X., Li Y., Xiang H., et al. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1alpha in MSCs. Biochem Biophys Res Commun 2010, 401:509-515.
45. Van Rechem C., Rood B.R., Touka M., Pinte S., Jenal M., Guerardel C., et al. Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1). J Biol Chem 2009, 284:20927-20935.
46. Zheng J., Wang J., Sun X., Hao M., Ding T., Xiong D., et al. HIC1 modulates prostate cancer progression by epigenetic modification. Clin Cancer Res 2013, 19:1400-1410.
47. Staton A.A., Knaut H., Giraldez A.J. miRNA regulation of Sdf1 chemokine signaling provides genetic robustness to germ cell migration. Nat Genet 2011, 43:204-211.
48. Liu L., Zhao X., Zhu X., Zhong Z., Xu R., Wang Z., et al. Decreased expression of miR-430 promotes the development of bladder cancer via the upregulation of CXCR7. Mol Med Rep 2013, 8:140-146.
49. Wang L., Zhang X., Jia L.T., Hu S.J., Zhao J., Yang J.D., et al. c-Myc-mediated epigenetic silencing of microRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology 2013, 59:1850-1863.
50. Luker K.E., Lewin S.A., Mihalko L.A., Schmidt B.T., Winkler J.S., Coggins N.L., et al. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 2012, 31:4750-4758.
51. Drury L.J., Ziarek J.J., Gravel S., Veldkamp C.T., Takekoshi T., Hwang S.T., et al. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc Natl Acad Sci U S A 2011, 108:17655-17660.
52. Heinrich E.L., Lee W., Lu J., Lowy A.M., Kim J. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J Transl Med 2012, 10:68.
53. Hernandez L., Magalhaes M.A., Coniglio S.J., Condeelis J.S., Segall J.E. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res 2011, 13:R128.
54. Liberman J., Sartelet H., Flahaut M., Muhlethaler-Mottet A., Coulon A., Nyalendo C., et al. Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma. PLoS ONE 2012, 7:e43665.
55. Dai X., Tan Y., Cai S., Xiong X., Wang L., Ye Q., et al. The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells. J Cell Mol Med 2011, 15:1299-1309.
56. Wang J., Shiozawa Y., Wang Y., Jung Y., Pienta K.J., Mehra R., et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008, 283:4283-4294.
57. Singh R.K., Lokeshwar B.L. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res 2011, 71:3268-3277.
58. Zheng K., Li H.Y., Su X.L., Wang X.Y., Tian T., Li F., et al. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2010, 29:31.
59. Maussang D., Mujic-Delic A., Descamps F.J., Stortelers C., Vanlandschoot P., Stigter-van Walsum M., et al. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. J Biol Chem 2013, 288:29562-29572.
60. Goguet-Surmenian E., Richard-Fiardo P., Guillemot E., Benchetrit M., Gomez-Brouchet A., Buzzo P., et al. CXCR7-mediated progression of osteosarcoma in the lungs. Br J Cancer 2013, 109:1579-1585.
61. Choi Y.H., Burdick M.D., Strieter B.A., Mehrad B., Strieter R.M. CXCR4, but not CXCR7, discriminates metastatic behavior in non-small cell lung cancer cells. Mol Cancer Res 2014, 12:38-47.
62. Zabel B.A., Wang Y., Lewen S., Berahovich R.D., Penfold M.E., Zhang P., et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol 2009, 183:3204-3211.
63. Zabel B.A., Lewen S., Berahovich R.D., Jaen J.C., Schall T.J. The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells. Mol Cancer 2011, 10:73.
64. Xue T.C., Chen R.X., Ren Z.G., Zou J.H., Tang Z.Y., Ye S.L. Transmembrane receptor CXCR7 increases the risk of extrahepatic metastasis of relatively well-differentiated hepatocellular carcinoma through upregulation of osteopontin. Oncol Rep 2013, 30:105-110.
65. Sanchez-Martin L., Sanchez-Mateos P., Cabanas C. CXCR7 impact on CXCL12 biology and disease. Trends Mol Med 2013, 19:12-22.
66. Cook L.B., Elemans M., Rowan A.G., Asquith B. HTLV-1: persistence and pathogenesis. Virology 2013, 435:131-140.
67. Jin Z., Nagakubo D., Shirakawa A.K., Nakayama T., Shigeta A., Hieshima K., et al. CXCR7 is inducible by HTLV-1 Tax and promotes growth and survival of HTLV-1-infected T cells. Int J Cancer 2009, 125:2229-2235.
68. Crawford D.H. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond Ser B Biol Sci 2001, 356:461-473.
69. Cohen J.I., Wang F., Mannick J., Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A 1989, 86:9558-9562.
70. Maier S., Staffler G., Hartmann A., Hock J., Henning K., Grabusic K., et al. Cellular target genes of Epstein-Barr virus nuclear antigen 2. J Virol 2006, 80:9761-9771.
71. Spender L.C., Lucchesi W., Bodelon G., Bilancio A., Karstegl C.E., Asano T., et al. Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells. J Gen Virol 2006, 87:2859-2867.
72. Lucchesi W., Brady G., Dittrich-Breiholz O., Kracht M., Russ R., Farrell P.J. Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2. J Virol 2008, 82:7456-7466.
73. Rickinson A.B., Young L.S., Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol 1987, 61:1310-1317.
74. Cancian L., Bosshard R., Lucchesi W., Karstegl C.E., Farrell P.J. C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7. PLoS Pathog 2011, 7:e1002164.
75. Zhao B., Mar J.C., Maruo S., Lee S., Gewurz B.E., Johannsen E., et al. Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc Natl Acad Sci U S A 2011, 108:337-342.
76. Ehlin-Henriksson B., Mowafi F., Klein G., Nilsson A. Epstein-Barr virus infection negatively impacts the CXCR4-dependent migration of tonsillar B cells. Immunology 2006, 117:379-385.
77. Li J., Zhang X.S., Xie D., Deng H.X., Gao Y.F., Chen Q.Y., et al. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression. Cancer Biol Ther 2007, 6:1997-2004.
78. Hengge U.R., Ruzicka T., Tyring S.K., Stuschke M., Roggendorf M., Schwartz R.A., et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002, 2:281-292.
79. Poole L.J., Yu Y., Kim P.S., Zheng Q.Z., Pevsner J., Hayward G.S. Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. J Virol 2002, 76:3395-3420.
80. Moses A.V., Jarvis M.A., Raggo C., Bell Y.C., Ruhl R., Luukkonen B.G., et al. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol 2002, 76:8383-8399.
81. Raggo C., Ruhl R., McAllister S., Koon H., Dezube B.J., Fruh K., et al. Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. Cancer Res 2005, 65:5084-5095.
82. Pablos J.L., Amara A., Bouloc A., Santiago B., Caruz A., Galindo M., et al. Stromal-cell derived factor is expressed by dendritic cells and endothelium in human skin. Am J Pathol 1999, 155:1577-1586.
83. Punj V., Matta H., Schamus S., Tamewitz A., Anyang B., Chaudhary P.M. Kaposi's sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 suppresses CXCR4 expression by upregulating miR-146a. Oncogene 2010, 29:1835-1844.
84. Yao L., Salvucci O., Cardones A.R., Hwang S.T., Aoki Y., De La Luz Sierra M., et al. Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis. Blood 2003, 102:3900-3905.
85. Wang J.F., Liu Z.Y., Anand A.R., Zhang X., Brown L.F., Dezube B.J., et al. Alpha-chemokine-mediated signal transduction in human Kaposi's sarcoma spindle cells. Biochim Biophys Acta 2004, 1691:129-139.
86. Munger K., Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res 2002, 89:213-228.
87. Vargas-Parada L. Pathology three questions. Nature 2012, 488:S14-S15.
88. Hernandez P.A., Gorlin R.J., Lukens J.N., Taniuchi S., Bohinjec J., Francois F., et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 2003, 34:70-74.
89. Balabanian K., Lagane B., Pablos J.L., Laurent L., Planchenault T., Verola O., et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 2005, 105:2449-2457.
90. Chow K.Y., Brotin E., Ben Khalifa Y., Carthagena L., Teissier S., Danckaert A., et al. A pivotal role for CXCL12 signaling in HPV-mediated transformation of keratinocytes: clues to understanding HPV-pathogenesis in WHIM syndrome. Cell Host Microbe 2010, 8:523-533.
91. Amine A., Rivera S., Opolon P., Dekkal M., Biard D.S., Bouamar H., et al. Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells. PLoS ONE 2009, 4:e5018.
92. Bollag W.B., Hill W.D. CXCR4 in epidermal keratinocytes: crosstalk within the skin. J Invest Dermatol 2013, 133:2505-2508.
93. Zhong C., Wang J., Li B., Xiang H., Ultsch M., Coons M., et al. Development and preclinical characterization of a humanized antibody targeting CXCL12. Clin Cancer Res 2013, 19:4433-4445.
94. Hachet-Haas M., Balabanian K., Rohmer F., Pons F., Franchet C., Lecat S., et al. Small neutralizing molecules to inhibit actions of the chemokine CXCL12. J Biol Chem 2008, 283:23189-23199.
95. Pusic I., DiPersio J.F. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol 2010, 17:319-326.
96. Wong D., Korz W. Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 2008, 14:7975-7980.
97. Gravel S., Malouf C., Boulais P.E., Berchiche Y.A., Oishi S., Fujii N., et al. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J Biol Chem 2010, 285:37939-37943.
98. Kalatskaya I., Berchiche Y.A., Gravel S., Limberg B.J., Rosenbaum J.S., Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 2009, 75:1240-1247.
99. Yoshikawa Y., Oishi S., Kubo T., Tanahara N., Fujii N., Furuya T. Optimized method of G-protein-coupled receptor homology modeling: its application to the discovery of novel CXCR7 ligands. J Med Chem 2013, 56:4236-4251.
100. Hao M., Zheng J., Hou K., Wang J., Chen X., Lu X., et al. Role of chemokine receptor CXCR7 in bladder cancer progression. Biochem Pharmacol 2012, 84:204-214.